<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158050">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01871493</url>
  </required_header>
  <id_info>
    <org_study_id>14833</org_study_id>
    <secondary_id>I6O-FW-BHBA</secondary_id>
    <nct_id>NCT01871493</nct_id>
  </id_info>
  <brief_title>A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Pharmacokinetics of LY2605541 Injection and Insulin Lispro Injection Administered as Mixture or as Individual Components in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>Singapore: Health Sciences Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate how the body absorbs and removes LY2605541,
      insulin lispro, and a mixture of both from the blood.  The study has two parts.
      Participants may enroll in only one part.  Each part has four treatment periods in a fixed
      order.  The study  will last approximately 8 weeks, not including screening.  Screening is
      required within 28 days prior to the start of the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Time to Reach Peak Concentration (tmax) of LY2605541 and Insulin Lispro</measure>
    <time_frame>Pre-dose up to 216 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY2605541 and Insulin Lispro</measure>
    <time_frame>Pre-dose up to 216 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-âˆž) of LY2605541 and Insulin Lispro</measure>
    <time_frame>Pre-dose up to 216 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Glucose Infusion Rate (Rmax)</measure>
    <time_frame>Predose up to 32 hours post clamp procedure in all treatment periods</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Glucose Infused Over Clamp Duration (Gtot)</measure>
    <time_frame>Predose up to 32 hours post clamp procedure in all treatment periods</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>LY2605541-Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.42 units per kilogram (U/kg) of LY2605541 given once daily (QD) for 1 day, subcutaneously (SQ) in 1 of 4 treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Lispro-Part A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose 0.36 U/kg of insulin lispro given QD for 1 day, SQ in 1 of 4 treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2605541/Lispro Mix 1-Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 0.54  U/kg of LY2605541 and 0.36 U/kg insulin lispro mixture given QD for 1 day, SQ in 1 of 4 treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2605541/Lispro Mix 2-Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 1.42 U/kg of LY2605541 and 0.36 insulin lispro mixture given QD for 1 day, SQ in 1 of 4 treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Lispro-Part B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.18 U/kg insulin lispro given twice daily (BID) for 1 day, SQ in 1 of 4 treatment periods.  Part B is contingent on data from Part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2605541/Lispro Mix-Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.71 U/kg LY2605541 and 0.18 U/kg insulin lispro mixture given BID for 1 day, SQ in 1 of 4 treatment periods.  Part B is contingent on data from Part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2605541 QD-Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.54 U/kg of LY2605541 given QD for 1 day, SQ in 1 of 4 treatment periods.  Part B is contingent on data from Part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2605541 BID-Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.71 U/kg  of LY2605541 given BID for 1 day SQ in 1 of 4 treatment periods.  Part B is contingent on data from Part A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2605541</intervention_name>
    <description>Administered subcutaneous (SQ)</description>
    <arm_group_label>LY2605541-Part A</arm_group_label>
    <arm_group_label>LY2605541/Lispro Mix 1-Part A</arm_group_label>
    <arm_group_label>LY2605541/Lispro Mix 2-Part A</arm_group_label>
    <arm_group_label>LY2605541/Lispro Mix-Part B</arm_group_label>
    <arm_group_label>LY2605541 QD-Part B</arm_group_label>
    <arm_group_label>LY2605541 BID-Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>Administered SQ</description>
    <arm_group_label>Insulin Lispro-Part A</arm_group_label>
    <arm_group_label>LY2605541/Lispro Mix 1-Part A</arm_group_label>
    <arm_group_label>LY2605541/Lispro Mix 2-Part A</arm_group_label>
    <arm_group_label>Insulin Lispro-Part B</arm_group_label>
    <arm_group_label>LY2605541/Lispro Mix-Part B</arm_group_label>
    <other_name>Humalog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are not of child-bearing potential

          -  Have a body mass index (BMI) between 18 and 29.9 kilograms per meter squared
             (kg/m^2), inclusive

          -  Are nonsmokers or have not smoked for at least 2 months prior to entering the study

        Exclusion Criteria:

          -  Have known allergies to insulin or its excipients, or related drugs, or history of
             relevant allergic reactions of any origin

          -  Have a history of first-degree relatives known to have diabetes mellitus

          -  Have used systemic glucocorticoids within 3 months prior to entry into the study

          -  Have donated blood or had a blood loss of 450 milliliter (mL) within 1 month prior to
             study enrollment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <zip>117597</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>June 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin LISPRO</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
